AbbVie (ABBV) Stock Forecast & Price Target

AbbVie is expected to see strong revenue growth in the mid-term, driven by its diversified product portfolio and a strong outlook in both the immunology and oncology segments. The recent acquisitions of Allergan, Cerevel, and ImmunoGen also add valuable assets to the company's portfolio and could potentially generate further growth opportunities. However, there are downside risks, such as commercial execution on key assets and potential setbacks in clinical data or regulatory approvals. Analysts have revised their estimates for AbbVie based on prescription data and conversations with the company, and expect an in-line quarter for 1Q 2026 with EPS of $2.57. The company's strong position in the neuroscience market and potential for life cycle management of key products such as Vraylar support an Overweight rating.

AbbVie is expected to report 1st quarter earnings in line on April 29th, and given their recent acquisition of Allergan as well as Cerevel and ImmunoGen, their oncology and neuroscience segments are expected to grow, which has led to a modest increase in their price target to $249. However, their exposure to the immunology market, specifically Humira, is a cause for concern as the drug faces potential biosimilar competition, which could greatly impact AbbVie's financial performance in the mid-term. As such, a negative outlook is warranted.